Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

Not Applicable

Terminated

• Conditions: Prostate Cancer
• Interventions: Device: Multiparametric MRI

• Registration Number: NCT03180398
• Lead Sponsor: Henry Ford Health System

Brief Summary

This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

Detailed Description

The study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Study Timeline

• Study First Submitted: 2017-06-05
• Study First Submitted QC: 2017-06-06
• Study First Posted: 2017-06-08
• Study Start: 2017-10-04
• Primary Completion: 2022-02-15
• Study Completion: 2022-02-15
• Results First Submitted: 2023-03-20
• Status Verified: 2023-09
• Results First Submitted QC: 2023-09-21
• Last Update Submitted: 2023-09-21
• Results First Posted: 2023-10-12
• Last Update Posted: 2023-10-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 9

Inclusion Criteria

• Histologically confirmed prostate adenocarcinoma

Exclusion Criteria

• Patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Multi-parametric MRI for Prostate Cancer	Multiparametric MRI	MRI will be acquired for prostate cancer patients undergoing radiation treatment.

Primary Outcome Measures

Name	Time	Method
Detection of Imaging Biomarkers to Localize the Intraprostatic Lesions and Predict Radiation Treatment Response	2 years	Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.
Tumor Response	2 years	Tumor response as measured by an increase in PSA.

Trial Locations

Locations (1)

Henry Ford Health System; 🇺🇸 Detroit, Michigan, United States